ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

16 träffar

Bibliografisk träff 2024-04-18

Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers.

Jia H, Deng W, Hao B, Cai M, Guo D, Cai Y, Dai X, Wu Z, He W, Wang J, Wang G, Xia S, Li N, Su W, Dai G.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.3c00553

Bibliografisk träff 2024-04-02

Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.

Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL.

Eur J Med Chem · research-article; journal article · DOI 10.1016/j.ejmech.2024.116357

Bibliografisk träff 2023-11-02

Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK).

Wang Z, Qu S, Yuan J, Tian W, Xu J, Tao R, Sun S, Lu T, Tang W, Zhu Y.

Bioorg Med Chem · review; journal article · DOI 10.1016/j.bmc.2023.117514

Bibliografisk träff 2023-07-19

A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.

Sutherland JJ, Yonchev D, Fekete A, Urban L.

Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-023-40064-9

Bibliografisk träff 2021-01-22

Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.

Xie Z, Yang X, Duan Y, Han J, Liao C.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c01511

Bibliografisk träff 2017-12-08

In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases.

Wells CI, Kapadia NR, Couñago RM, Drewry DH.

Medchemcomm · review-article; review; journal article · DOI 10.1039/c7md00510e

Bibliografisk träff 2017-12-01

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368

Bibliografisk träff 2015-02-14

LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors.

Li GB, Ji S, Yang LL, Zhang RJ, Chen K, Zhong L, Ma S, Yang SY.

Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2015.02.019

Bibliografisk träff 2014-09-06

4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.

Puig de la Bellacasa R, Roué G, Balsas P, Pérez-Galán P, Teixidó J, Colomer D, Borrell JI.

Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2014.09.018

Bibliografisk träff 2014-04-29

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.

Currie KS, Kropf JE, Lee T, Blomgren P, Xu J, Zhao Z, Gallion S, Whitney JA, Maclin D, Lansdon EB, Maciejewski P, Rossi AM, Rong H, Macaluso J, Barbosa J, Di Paolo JA, Mitchell SA.

J Med Chem · journal article · DOI 10.1021/jm500228a

Bibliografisk träff 2014-04-03

Syk inhibitors with high potency in presence of blood.

Thoma G, Blanz J, Bühlmayer P, Drückes P, Kittelmann M, Smith AB, van Eis M, Vangrevelinghe E, Zerwes HG, Che JJ, He X, Jin Y, Lee CC, Michellys PY, Uno T, Liu H.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2014.03.075

Bibliografisk träff 2013-10-03

Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O, Marker DF, Dewhurst S, Gelbard HA.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/jm401094t

Bibliografisk träff 2012-09-07

Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.

Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.112.047068

Bibliografisk träff 2012-02-14

Discovery and development of spleen tyrosine kinase (SYK) inhibitors.

Singh R, Masuda ES, Payan DG.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm201271b

Bibliografisk träff 2011-10-30

Comprehensive analysis of kinase inhibitor selectivity.

Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.

Nat Biotechnol · journal article · DOI 10.1038/nbt.1990

Bibliografisk träff 2009-02-20

Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.

Xie HZ, Li LL, Ren JX, Zou J, Yang L, Wei YQ, Yang SY.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2009.02.049